CA2606315A1 - Use of phycotoxins in veterinary applications - Google Patents
Use of phycotoxins in veterinary applications Download PDFInfo
- Publication number
- CA2606315A1 CA2606315A1 CA002606315A CA2606315A CA2606315A1 CA 2606315 A1 CA2606315 A1 CA 2606315A1 CA 002606315 A CA002606315 A CA 002606315A CA 2606315 A CA2606315 A CA 2606315A CA 2606315 A1 CA2606315 A1 CA 2606315A1
- Authority
- CA
- Canada
- Prior art keywords
- gtx
- effective amount
- activity
- units
- muscle
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Pharmaceutical compositions comprising tricyclic 3,4-propinoperhydropurines and uses thereof which for providing a local anesthetic, muscle relaxant, facilitating wound healing, and immobilization to an animal are provided. Also provided are a variety of methods of treating animals using the compositions of the invention.
Description
USE OF PHYCOTOXINS IN VETERINARY APPLICATIONS
FIELD OF THE INVENTION
This invention relates to methods of using tricyclic 3,4-propinoperhydropurines in the treatment of veterinary conditions.
BACKGROUND OF THE INVENTION
Paralytic shellfish poisoning (PSP) results from a mixture of phycotoxins that bind reversibly to a receptor site on the voltage-gated sodium channel found in excitable cells. The primary clinical symptom is an acute paralytic illness.
Phycotoxins or algal toxins are produced by microscopic planktonic algae.
These toxins accumulate on filter feeders such as bivalves. Consumption of phycotoxin-contaminated shellfish results in six diseases in humans: PSP, diarrhetic shellfish poisoning (DSP), amnesic shellfish poisoning (ASP), neurotoxic shellfish poisoning (NSP), ciguatera poisoning (CP) and cyanobacterial poisoning (CNP).
The phycotoxins that produce PSP have a cominon structure of 3,4,6-trialquil tetrahidropurine. The gonyautoxins (GTX) are the most abundant phycotoxins found in shellfish extract, accounting for over 80% of the total toxin content.
The high toxicity of the phycotoxins is due to the reversible binding to a receptor site on the voltage-gated sodium channel on excitable cells, thus bloclcing the influx of sodium ions and preventing nerve and muscle cells from producing action potentials, thereby blocking neuronal transmission and causing deatll in mammals via respiratory arrest and cardiovascular shock. Application of small amounts of PSP
toxin produces a flaccid paralysis of striated muscle for periods that are dose dependant.
Wound healing is effected by muscle tension. Reduction of the muscle tension on a wound may lead to less scar formation as well as less discomfort in the healing process. Similarly, relaxation of muscle tissue may be beneficial in bone healing, particularly when muscle tension may lead to fracture displacement.
Reduction of the pain associated with wound or fracture healing may be of particular benefit in animals encountered in a typical veterinary practice. These animals include the large and small animals such as cattle, horses, sheep, swine, cats and dogs, but also increasingly exotic pets such as ampliibians, reptiles and birds.
SUMMARY OF THE INVENTION
In accordance with the objects of the invention, novel methods for the use of paralytic sliellfish poisons are provided.
In one aspect of the invention, methods of treating aiiimals in need of such treatment with compositions of the invention including one or more tricyclic 3,4-propinoperhydropurines are provided.
In another aspect of the invention, methods of treating animals in need of such treatment with compositions of the invention used in combination with an effective amount of a neurotoxin and/or a local anesthetic are provided.
DETAILED DESCRIPTION OF THE INV.ENTION
In accordance with the present invention, it has been found that compositions comprising heterocyclic guanidine-type compounds, and more specifically tricyclic 3,4-propinoperhydropurines, can be used for many veterinary applications, reducing the need for surgery, and/or minimizing side effects, allergies, immune rejection or hematoma. The compositions of the invention may be used to treat conditions in animals including, but not limited to any condition where muscle relaxation iinproves the recovery prognosis/process, muscular spasm-related pain management, inuscular spasms, animal immobilization and iinproved wound and bone fracture healing In accordance with the present invention, muscular relaxation is immediate, usually occurring in less than five minutes. The compositions of the present invention may also be used as a local anesthetic where general anesthesia is not needed or may be harmful or dangerous to the animal in question.
Before describing the present invention in detail, it is to be understood that this invention is not limited to specific drug delivery systems, device structures, enhancers or carriers, as such may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting.
It must be noted that, as used in this specification and the appended claims, the singular forms "a," "an" and "the" include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to "a pharmacologically active agent" includes a mixture of two or more active agents, reference to "an enhancer"
includes mixtures of two or more enhancers, and the lilce.
FIELD OF THE INVENTION
This invention relates to methods of using tricyclic 3,4-propinoperhydropurines in the treatment of veterinary conditions.
BACKGROUND OF THE INVENTION
Paralytic shellfish poisoning (PSP) results from a mixture of phycotoxins that bind reversibly to a receptor site on the voltage-gated sodium channel found in excitable cells. The primary clinical symptom is an acute paralytic illness.
Phycotoxins or algal toxins are produced by microscopic planktonic algae.
These toxins accumulate on filter feeders such as bivalves. Consumption of phycotoxin-contaminated shellfish results in six diseases in humans: PSP, diarrhetic shellfish poisoning (DSP), amnesic shellfish poisoning (ASP), neurotoxic shellfish poisoning (NSP), ciguatera poisoning (CP) and cyanobacterial poisoning (CNP).
The phycotoxins that produce PSP have a cominon structure of 3,4,6-trialquil tetrahidropurine. The gonyautoxins (GTX) are the most abundant phycotoxins found in shellfish extract, accounting for over 80% of the total toxin content.
The high toxicity of the phycotoxins is due to the reversible binding to a receptor site on the voltage-gated sodium channel on excitable cells, thus bloclcing the influx of sodium ions and preventing nerve and muscle cells from producing action potentials, thereby blocking neuronal transmission and causing deatll in mammals via respiratory arrest and cardiovascular shock. Application of small amounts of PSP
toxin produces a flaccid paralysis of striated muscle for periods that are dose dependant.
Wound healing is effected by muscle tension. Reduction of the muscle tension on a wound may lead to less scar formation as well as less discomfort in the healing process. Similarly, relaxation of muscle tissue may be beneficial in bone healing, particularly when muscle tension may lead to fracture displacement.
Reduction of the pain associated with wound or fracture healing may be of particular benefit in animals encountered in a typical veterinary practice. These animals include the large and small animals such as cattle, horses, sheep, swine, cats and dogs, but also increasingly exotic pets such as ampliibians, reptiles and birds.
SUMMARY OF THE INVENTION
In accordance with the objects of the invention, novel methods for the use of paralytic sliellfish poisons are provided.
In one aspect of the invention, methods of treating aiiimals in need of such treatment with compositions of the invention including one or more tricyclic 3,4-propinoperhydropurines are provided.
In another aspect of the invention, methods of treating animals in need of such treatment with compositions of the invention used in combination with an effective amount of a neurotoxin and/or a local anesthetic are provided.
DETAILED DESCRIPTION OF THE INV.ENTION
In accordance with the present invention, it has been found that compositions comprising heterocyclic guanidine-type compounds, and more specifically tricyclic 3,4-propinoperhydropurines, can be used for many veterinary applications, reducing the need for surgery, and/or minimizing side effects, allergies, immune rejection or hematoma. The compositions of the invention may be used to treat conditions in animals including, but not limited to any condition where muscle relaxation iinproves the recovery prognosis/process, muscular spasm-related pain management, inuscular spasms, animal immobilization and iinproved wound and bone fracture healing In accordance with the present invention, muscular relaxation is immediate, usually occurring in less than five minutes. The compositions of the present invention may also be used as a local anesthetic where general anesthesia is not needed or may be harmful or dangerous to the animal in question.
Before describing the present invention in detail, it is to be understood that this invention is not limited to specific drug delivery systems, device structures, enhancers or carriers, as such may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting.
It must be noted that, as used in this specification and the appended claims, the singular forms "a," "an" and "the" include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to "a pharmacologically active agent" includes a mixture of two or more active agents, reference to "an enhancer"
includes mixtures of two or more enhancers, and the lilce.
In describing and claiming the present invention, the following terminology will be used in accordance with the defniitions set out below.
The terms "treating" and "treatment" as used herein refer to reduction in severity and/or frequency of symptoms, elimination of symptoms and/or underlying cause, prevention of the occurrence of symptoms and/or their underlying cause, and improvement or remediation of damage. The present method of "treating" an animal, as the term is used herein, thus encompasses both prevention of one or more symptoms or underlying causes in a predisposed animal, as well as treatment of one or more symptoms or underlying causes in a clinically symptomatic animal.
The terms "active," "active agent," "drug" and "pharmacologically active agent" are used interchangeably herein to refer to a chemical material or coinpound that induces a desired effect, and include agents that are therapeutically effective, prophylactically effective, or cosmetically effective. Also included are derivatives, metabolites and analogs of those compounds or classes of compounds specifically mentioned which also induce the desired effect.
By "therapeutically effective" amount is meant a nontoxic but sufficient amount of an active agent to provide the desired therapeutic effect.
By "transdermal" drug delivery is meant administration of a drug to the skin surface of an animal so that the drug passes through the skin tissue and into the animal's blood streain, thereby producing a systemic effect. The term "transdermal" is intended to include "transmucosal" drug administration, i.e., administration of a drug to the inucosal (e.g., sublingual, buccal, vaginal, rectal) surface of an individual so that the drug passes through the inucosal tissue and into the individual's blood stream.
The term "topical administration" is used in its conventional sense to mean delivery of a topical drug of a pharmacologically active agent to the skin or mucosa, as in, for example, the treatment of various skin disorders. Topical drug administration, in contrast to transdermal administration, provides a local rather than a systemic effect. Unless otherwise stated or implied, the terms "topical drug administration" and "transdermal drug administration" are used interchangeably.
As used herein, "an effective amoiuit" is that amount sufficient to interfere with neuronal transmission by blocking the presynaptic release of the neurotransmitter acetylcholine in the neuromuscular plate, tllus interfering with transmission, paralyzing the muscle and preventing it from contracting, or producing a relaxation of contracted muscles. Amounts are given in units of activity. One unit of activity corresponds to an amount of the coinposition of the invention necessary to block the muscular contractions of the crural biceps of a BALB-C strain mouse leg for 1.5 to 2.0 hours.
"Carriers" or "vehicles" as used herein refer to carrier materials suitable for transdennal drug administration. Carriers and vehicles useful herein include any such materials known in the art, which is nontoxic and does not interact with other components of the composition in a deleterious manner.
The teiTn "aqueous" refers to a fonnulation or drug delivery system that contains water or that becomes water-containing following application to the slcin or mucosal tissue.
The compositions of the invention coinprise an effective ainount of at least one tricyclic 3,4-propinoperhydropurine (represented by formula (I) set forth below:
CH-) ~
Rl- N NH N+
>-H2 H N}~~ N NH
'OH
RaR3 Formula (I) wherein Rl and R5 are independently selected from the group consisting of -H
and -OH; RZ and R3 are independently selected from the group consisting of -H and -SO3i and R.Q. is selected from the group consisting of-H, -OH, -COONH2, -COONHSO"3 and -COOCH3, with the proviso that either one of R2 and R3 must be -OSO"3, or R4 must be -COONHSO-3, and a pharmacologically acceptable topical carrier.
Preferred tricyclic 3,4-propinoperhydropurines in accordance with the present invention are the gonyautoxins (hereinafter "GTX") of the formula (I) as set forth in the table below.
The terms "treating" and "treatment" as used herein refer to reduction in severity and/or frequency of symptoms, elimination of symptoms and/or underlying cause, prevention of the occurrence of symptoms and/or their underlying cause, and improvement or remediation of damage. The present method of "treating" an animal, as the term is used herein, thus encompasses both prevention of one or more symptoms or underlying causes in a predisposed animal, as well as treatment of one or more symptoms or underlying causes in a clinically symptomatic animal.
The terms "active," "active agent," "drug" and "pharmacologically active agent" are used interchangeably herein to refer to a chemical material or coinpound that induces a desired effect, and include agents that are therapeutically effective, prophylactically effective, or cosmetically effective. Also included are derivatives, metabolites and analogs of those compounds or classes of compounds specifically mentioned which also induce the desired effect.
By "therapeutically effective" amount is meant a nontoxic but sufficient amount of an active agent to provide the desired therapeutic effect.
By "transdermal" drug delivery is meant administration of a drug to the skin surface of an animal so that the drug passes through the skin tissue and into the animal's blood streain, thereby producing a systemic effect. The term "transdermal" is intended to include "transmucosal" drug administration, i.e., administration of a drug to the inucosal (e.g., sublingual, buccal, vaginal, rectal) surface of an individual so that the drug passes through the inucosal tissue and into the individual's blood stream.
The term "topical administration" is used in its conventional sense to mean delivery of a topical drug of a pharmacologically active agent to the skin or mucosa, as in, for example, the treatment of various skin disorders. Topical drug administration, in contrast to transdermal administration, provides a local rather than a systemic effect. Unless otherwise stated or implied, the terms "topical drug administration" and "transdermal drug administration" are used interchangeably.
As used herein, "an effective amoiuit" is that amount sufficient to interfere with neuronal transmission by blocking the presynaptic release of the neurotransmitter acetylcholine in the neuromuscular plate, tllus interfering with transmission, paralyzing the muscle and preventing it from contracting, or producing a relaxation of contracted muscles. Amounts are given in units of activity. One unit of activity corresponds to an amount of the coinposition of the invention necessary to block the muscular contractions of the crural biceps of a BALB-C strain mouse leg for 1.5 to 2.0 hours.
"Carriers" or "vehicles" as used herein refer to carrier materials suitable for transdennal drug administration. Carriers and vehicles useful herein include any such materials known in the art, which is nontoxic and does not interact with other components of the composition in a deleterious manner.
The teiTn "aqueous" refers to a fonnulation or drug delivery system that contains water or that becomes water-containing following application to the slcin or mucosal tissue.
The compositions of the invention coinprise an effective ainount of at least one tricyclic 3,4-propinoperhydropurine (represented by formula (I) set forth below:
CH-) ~
Rl- N NH N+
>-H2 H N}~~ N NH
'OH
RaR3 Formula (I) wherein Rl and R5 are independently selected from the group consisting of -H
and -OH; RZ and R3 are independently selected from the group consisting of -H and -SO3i and R.Q. is selected from the group consisting of-H, -OH, -COONH2, -COONHSO"3 and -COOCH3, with the proviso that either one of R2 and R3 must be -OSO"3, or R4 must be -COONHSO-3, and a pharmacologically acceptable topical carrier.
Preferred tricyclic 3,4-propinoperhydropurines in accordance with the present invention are the gonyautoxins (hereinafter "GTX") of the formula (I) as set forth in the table below.
Compound Ri R2 R3 R4 R5 Gonyautoxin 1 -OH -H -OSO"3 -COONH2 -OH
Gonyautoxin 2 -H -H -OSO-3 -COONH2 -OH
Gonyautoxin 3 -H -OSO-3 -H -COONH2 -OH
Gonyautoxin 4 -OH -OSO-3 -H -COONH2 -OH
Gonyautoxin 5 -H -H -H -COONHSO"3 -OH
In one aspect of the invention, the veterinary compositions of the invention comprise at least one GTX compound selected from GTX 1, GTX 2, GTX 3, GTX 4 and GTX 5. In other aspects of the invention, the veterinary compositions comprise a mixture of tricyclic 3,4-propinoperhydropurines. For example, mixtures of two or more GTX compounds are contemplated. It should be understood by those of slcill in the art that, subject to the conditions set forth with respect to the fomiula (I) above, other mixtures and combinations of tricyclic 3,4-propinoperhydropurines are within the scope of this invention. Unlike Botulin A toxin, these preparations are stable at room teinperature, do not require refrigeration, are sterilizable, are substantially non-allergenic, are not peptide in nature and thus are substantially non-allergenic, act substantially immediately, and may be applied repeatedly without significant, adverse side effects.
The coinpounds of the formula (I) may be purified fioin dinflagellates, cyanobacterias and also may be accumulated by highly-contaminated mollusks, from which they may also be purified. Any pharmacologically acceptable carrier may be employed, including, but not limited to, water, acetic acid, and saline solutions.
Acetic acid and 0.09% sodium chloride solution are preferred carrier materials.
Alfernatively, the pliarmaceutical corripositions of the invention additionally comprise at least one coinpound selected from the group consisting of saxitoxin (STX), neosaxitoxin, decarbamoylsaxitoxin, tetrodotoxin, tetanus toxin, and Botulin A toxin, along with at least one GTX compound, and optionally, two or more GTX
compounds. The combination may be used in any of the applications in which the compositions of the invention are used. In another embodiment the compositions of the invention are used in combination with an effective amount of a local anesthetic.
Compositions of the invention may also be used in combination witli one or more neurotoxins and one or more local anesthetics, if desired.
Gonyautoxin 2 -H -H -OSO-3 -COONH2 -OH
Gonyautoxin 3 -H -OSO-3 -H -COONH2 -OH
Gonyautoxin 4 -OH -OSO-3 -H -COONH2 -OH
Gonyautoxin 5 -H -H -H -COONHSO"3 -OH
In one aspect of the invention, the veterinary compositions of the invention comprise at least one GTX compound selected from GTX 1, GTX 2, GTX 3, GTX 4 and GTX 5. In other aspects of the invention, the veterinary compositions comprise a mixture of tricyclic 3,4-propinoperhydropurines. For example, mixtures of two or more GTX compounds are contemplated. It should be understood by those of slcill in the art that, subject to the conditions set forth with respect to the fomiula (I) above, other mixtures and combinations of tricyclic 3,4-propinoperhydropurines are within the scope of this invention. Unlike Botulin A toxin, these preparations are stable at room teinperature, do not require refrigeration, are sterilizable, are substantially non-allergenic, are not peptide in nature and thus are substantially non-allergenic, act substantially immediately, and may be applied repeatedly without significant, adverse side effects.
The coinpounds of the formula (I) may be purified fioin dinflagellates, cyanobacterias and also may be accumulated by highly-contaminated mollusks, from which they may also be purified. Any pharmacologically acceptable carrier may be employed, including, but not limited to, water, acetic acid, and saline solutions.
Acetic acid and 0.09% sodium chloride solution are preferred carrier materials.
Alfernatively, the pliarmaceutical corripositions of the invention additionally comprise at least one coinpound selected from the group consisting of saxitoxin (STX), neosaxitoxin, decarbamoylsaxitoxin, tetrodotoxin, tetanus toxin, and Botulin A toxin, along with at least one GTX compound, and optionally, two or more GTX
compounds. The combination may be used in any of the applications in which the compositions of the invention are used. In another embodiment the compositions of the invention are used in combination with an effective amount of a local anesthetic.
Compositions of the invention may also be used in combination witli one or more neurotoxins and one or more local anesthetics, if desired.
Witliout being bound by theory, when applied locally, these compounds appear to effect the antispasmodic action by bloclcing the spreading of nervous impulse, or neuronal transmission, by reversibly binding to the sole biological molecular receptor, i.e. the voltage gated sodium channel, present in all neurons and excitable cells. By binding to this channel, there is no entry of sodium to the neuronal cell; depolarization does not occur and, therefore, propagation of the impulse is stopped. This action mechanism blocks the presynaptic release of the neurotransmitter acetylcholine in the neuromuscular plate, thus interfering with neuromuscular transmission, paralyzing the muscle and preventing it from contracting, or producing a relaxation of muscles contracted by pathological problems.
The pharmaceutical preparations of the invention are administered either transdermally or by injection, locally in the muscle or in the vicinity of the muscle that is to be paralyzed or prevented from contracting. The application should be in amounts sufficient to provide from 1-1000 units (U) of activity to the muscle, per dose. The effect is immediately apparent, generally occurring within a maximum of 30 seconds to five minutes after administration of the active compound to the treatment area. The maximum effect is generally achieved within 15 minutes of administration of the active compound to the treatment area. Its effective duration depends on the dose administered, the muscle in question, as well as the volume and specific composition administered. This is the pattern for substantially all veterinary applications and pathologies.
More preferably, each dose includes more than 32 units of activity up to a maxiinum of about 1000 units of activity. Even more preferably, each dose includes from about 50 to about 500 units of activity. Most preferably, each dose includes about 75 to about 200 units of activity. Doses may be repeated from time-to-time, as needed, to continue muscle relaxation until the desired effect is obtained.
According to one method of the present invention, mammals are treated by direct, local injection of a coinposition of the invention into a inuscle or in the vicinity of a muscle. Preferably, the muscle at the location of injection exhibits elevated tone or spasms, tliough this is not necessary for the effectiveness of all treatments. In a preferred embodiment, each injection should be limited to not more than two milliliters of composition, including solvents, adjuvants and/or carrier materials.
Administration may be accomplished, for example, using a one milliliter, tuberculin-type disposable syringe with a twenty-seven to thirty gauge needle.
Alternatively, for certain methods, it may be desirable to administer the dosage using an endoscope such as that described in U.S. Patent No. 5,674,205, the disclosure of which is hereby incoiporated by reference for the purpose of providing details of an endoscope suitable for use in the inethod of the present invention.
Alternatively, the pharmaceutical compositions of the invention may be applied locally to the skin for transdennal delivery. To form such a preparation, an effective amount of the pharnnaceutical compositions of the invention is added to a pharmacologically acceptable carrier. The composition, when applied to the skin, may be in any form suitable for application to the body surface, and may coinprise, for exainple, a cream, lotion, solution, gel, ointment, paste or the like, and/or may be prepared so as to contain liposomes, micelles, and/or microspheres. The composition may be directly applied to the body surface or may involve use of a drug delivery device. Thus, a fornnulation or drug reservoir may be aqueous, i.e., contain water, or may be nonaqueous and used in combination with an occlusive overlayer so that moisture evaporating from the body surface is maintained within the formulation or transdermal system during drug achninistration. In some cases, however, e.g., with an occlusive gel, a non-aqueous formulation may be used with or without an occlusive layer.
The delivery of drugs transdermally provides many advantages; primarily, such a means of delivery is a comfortable, convenient and noninvasive way of administering drugs. The variable rates of absorption and metabolism encountered in oral treatment are avoided, and other inherent inconveiuences--e.g., gastrointestinal irritation and the like--are eliminated as well. Transdermal drug delivery also makes possible a high degree of control over blood concentrations of any particular drug.
Slcin is a structurally complex, relatively thick membrane. Molecules moving from the enviromnent into and through intact slcin must first penetrate the stratum corneum and any material on its surface. They must then penetrate the viable epidermis, the papillary dermis, and the capillary walls into the blood stream or lymph channels. To be so absorbed, molecules must overcome a different resistance to penetration in each type of tissue. Transport across the skin membrane is thus a complex pllenomenon. However, it is the cells of the stratum corneum (the outer layer of the epidermis), which present the primary barrier to absorption of topical compositions or transdermally administered drugs. The stratum corneum is a thin layer of dense, highly keratinized cells approximately 10-15 microns thick over most of the body. It is believed to be the high degree of keratinization within these cells as well as their dense packing which creates in most cases a substantially impermeable barrier to drug penetration. With many drugs, the rate of permeation through the skin is extremely low without the use of some means to enhance the permeability of the skin.
In order to increase the rate at which a drug penetrates through the skin, then, various approaches have been followed, each of which involves the use of either a chemical penetration enhancer or a physical penetration enhancer. Physical enhancement of skin permeation includes, for example, electrophoretic techniques such as iontophoresis. Chemical enhancers are compounds that are administered along with the drug (or in some cases the skin may be pretreated with a chemical enhancer) in order to increase the permeability of the stratum comeum, and thereby provide for enhanced penetration of the drug through the skin. Ideally, such chemical penetration enhancers (or "permeation enhancers," as the compounds are referred to herein) are compounds that are innocuous and serve merely to facilitate diffusion of the drug through the stratum corneum.
In another aspect, the invention pertains to a method, composition and drug delivery system for increasing the rate at which the active agent, permeates through the body surface of a patient. The method involves administering the agent to a predetermined area of the patient's body surface in combination with a chemical permeation enhancer, such as a hydroxide-releasing agent in an amount effective to enhance the flux of the agent through the body surface without causing damage thereto, or in combination with an ultrasound treatment. Other suitable chemical permeation enhancers are described in, for example, W.R. Pfister and D.S. T.
Hsieh, - - - -"Permeation Enhancers Compatible with Transdermal Drug Delivery Systems, Part I:
Selection and Formulation Considerations," Pharnz. Technol., September 1990, and W.R. Pfister and D.S.T. Hsieh, "Permeation Enhancers Coinpatible with Transdermal Drug Delivery Systems, Part 11: System Design Considerations," Phaf=rn.
Technol., October 1990, the disclosures of which are hereby incorporated by reference to describe suitable chemical permeation enliancers.
Thus, the present method of transdermally delivering the active agent may vary, but necessarily involves application of a composition containing a tricyclic 3,4-propinoperhydropurine to a predetermined area of the skin or mucosal tissue for a period of time sufficient to provide an effective blood level or penetration level of drug. The method may involve direct application of the composition as an ointment, gel, cream, or the like, or may involve use of a drug delivery device as taught in the art, e.g., in U.S. Patent Nos. 4,915,950, 4,906,463, 5,091,186 or 5,246,705, the disclosures of which are hereby incorporated by reference for the purpose of describing specific transdermal drug delivery devices, or as described below.
Various compounds for enhancing the permeability of slcin are known in the art and can be used in the compositions of the present invention. Compounds that may be used to enhance slcin permeability include: the sulfoxides dimethylsulfoxide (DMSO) and decylmethylsulfoxide (Clo MSO); ethers such as diethylene glycol monoethyl ether (available commercially as TranscutolTM) and diethylene glycol monomethyl ether; surfactants such as sodium laurate, sodium lauryl sulfate, cetyltrimethylanunonium bromide, benzalkonium chloride, Poloxamer (231, 182, 184), Tween (20, 40, 60, 80) and lecithin (U.S. Pat. No. 4,783,450); the 1-substituted azacycloheptan-2-ones, particularly 1-n-dodecylcyclazacycloheptan-2-one (available under the trademarlc AzoneTM from Nelson Research & Development Co., Irvine, Calif.; see U.S. Pat. Nos. 3,989,816, 4,316,893, 4,405,616 and 4,557,934);
alcohols such as ethanol, propanol, octanol, benzyl alcohol, and the like; fatty acids such as lauric acid, oleic acid and valeric acid; fatty acid esters such as isopropyl myristate, isopropyl palmitate, methylpropionate, and ethyl oleate; polyols and esters thereof such as propylene glycol, ethylene glycol, glycerol, butanediol, polyethylene glycol, and polyethylene glycol monolaurate (PEGML; see, e.g., U.S. Pat. No.
4,568,343);
amides and other nitrogenous conlpounds such as urea, dimetlzylacetamide (DMA), diinethylformamide (DMF), 2-pyrrolidone, 1-methyl-2-pyrrolidone, ethanol amine, diethanol amine and triethanolamine; terpenes; alkanones, and organic acids, particularly salicylic acid and salicylates, citric acid and succinic acid.
Percutaneous Penetration Enhancers, eds. Smith et al. (CRC Press, 1995) provides an excellent overview of the field and further background information on a number of chemical and physical enhancers.
Transdermal Delivery Systems An alternative and preferred method for administering a tricyclic 3,4-propinoperhydropurine transdermally involves the use of a drug delivery system, e.g., a topical or transdermal "patch," wherein the active agent is contained within a laminated structure that is to be affixed to the slcin. In such a structure, the active agent is contained in a layer, or "reservoir," underlying an upper backing layer. The laininated structure may contain a single reservoir, or it may contain multiple reservoirs.
In one embodiment, the reservoir comprises a polymeric matrix of a pharmaceutically acceptable adhesive material that serves to affix the system to the skin during drug delivery; typically, the adhesive material is a pressure-sensitive adhesive (PSA) that is suitable for long-term slcin contact, and which should be physically and chemically coinpatible with the active agent, hydroxide-releasing agent, and any carriers, vehicles or other additives that are present.
Examples of suitable adhesive materials include, but are not limited to, the following:
polyethylenes; polysiloxanes; polyisobutylenes; polyacrylates;
polyacrylamides;
polyurethanes; plasticized ethylene-vinyl acetate copolymers; and tacky rubbers such as polyisobutene, polybutadiene, polystyrene-isoprene copolymers, polystyrene-butadiene copolymers, and neoprene (polychloroprene). Preferred adhesives are polyisobutylenes.
The backing layer functions as the primary structural element of the transdermal system and provides the device with flexibility an, preferably, occlusivity. The material used for the baclcing layer should be inert and incapable of absorbing drug, hydroxide-releasing agent or components of the formulation contained within the device. The backing is preferably comprised of a flexible elastoineric material that serves as a protective covering to prevent loss of drug and/or vehicle via transmission tlirough the upper surface of the patch, and will preferably impart a degree of occlusivity to the system, such that the area of the body surface covered by the patch becomes hydrated during use. The material used for the backing layer should permit the device to follow the contours of the slcin and be worn comfortably on areas of slcin such as at joints or other points of flexure, that are normally subjected to mechanical strain with little or no likelihood of the device disengaging from the skin due to differences in the flexibility or resiliency of the skin and the device. The materials used as the backing layer are either occlusive or peimeable, as noted above, although occlusive baclcings are preferred, and are generally derived from synthetic polymers (e.g., polyester, polyethylene, polypropylene, polyurethane, polyvinylidine chloride, and polyether amide), natural polymers (e.g., cellulosic materials), or macroporous woven and nonwoven materials.
During storage and prior to use, the laminated structure includes a release liner. Immediately prior to use, this layer is removed from the device so that the system may be affixed to the slcin. The release liner should be made from a drug/vehicle impermeable material, and is a disposable element which serves only to protect the device prior to application. Typically, the release liner is formed from a material impermeable to the pharmacologically active agent and the hydroxide-releasing agent, and which is easily stripped from the transdermal patch prior to use.
In an alternative embodiment, the drug-containing reservoir and slcin contact adhesive are present as separate and distinct layers, with the adhesive underlying the reservoir. In such a case, the reservoir may be a polymeric matrix as described above.
Alternatively, the reservoir may be comprised of a liquid or semisolid formulation contained in a closed compartment or "pouch," or is may be a hydrogel reservoir, or may take some other form. Hydrogel reservoirs are particularly preferred herein. As will be appreciated by those skilled in the art, hydrogels are macromolecular networlcs that absorb water and thus swell but do not dissolve in water. That is, hydrogels contain hydrophilic functional groups that provide for water absorption, but the hydrogels are comprised of crosslinked polymers that give rise to aqueous insolubility. Generally, then, hydrogels are comprised of crosslinked hydrophilic polymers such as a polyurethane, a polyvinyl alcohol, a polyacrylic acid, a polyoxyethylene, a polyvinylpyrrolidone, a poly(hydroxyethyl methacrylate) (poly(HEMA)), or a copolymer or mixture thereof Particularly preferred hydrophilic polymers are copolymers of HEMA and polyvinylpyrrolidone.
Additional layers, e.g., intermediate fabric layers and/or rate-controlling membranes, may also be present in any of these drug delivery systems. Fabric layers may be used to facilitate fabrication of the device, while a rate-controlling membrane may be used to control the rate at which a component permeates out of the device.
The component may be a drug, a hydroxide-releasing agent, an additional enhancer, or some other component contained in the drug delivery system.
A rate-controlling membrane, if present, will be included in the system on the skin side of one or more of the drug reservoirs. The materials used to form such a membrane are selected to limit the flux of one or more components contained in the drug formulation. Representative materials useful for forming rate-controlling membranes include polyolefins such as polyethylene and polypropylene, polyamides, polyesters, ethylene-ethacrylate copolymer, ethylene-vinyl acetate copolymer, ethylene-vinyl methylacetate copolymer, ethylene-vinyl ethylacetate copolymer, ethylene-vinyl propylacetate copolymer, polyisoprene, polyacrylonitrile, ethylene-propylene copolymer, and the like.
Generally, the underlying surface of the transdermal device, i.e., the skin contact area, has an area in the range of about 5 cm2 to 200 cm2, preferably 5 cm2 to 100 cm2, more preferably 20 cm2 to 60 cm2. That area will vary, of course, with the amount of the drug to be delivered and the flux of the drug through the body surface.
Larger patches will be necessary to accommodate larger quantities of drug, while smaller patches can be used for small quantities of drug and/or drugs that exhibit a relatively high permeation rate.
Such drug delivery systems may be fabricated using conventional coating and laminating techniques known in the art. For example adhesive matrix systems can be prepared by casting a fluid admixture adhesive, drug and vehicle onto the backing layer followed by lamination of the release liner. Similarly the adhesive mixture may be cast onto the release liner, followed by lamination of the release liner.
Alternatively, the drug reservoir may be prepared in the absence of drug or excipient, and then loaded by "soaking" in a drug/vehicle mixture. In general, transdermal systems of the invention are fabricated by solvent evaporation, film casting, melt extrusion, thin film lamination, die cutting, or the like. The hydroxide-releasing agent will generally be incorporated into the device during patch manufacture rather than subsequent to preparation of the device. For active agents that are obtained in salt form, an enhancer that doubles as a neutralizing agent is incorporated into the device during patch manufacture rather than subsequent to preparation of the device.
Thus, for acid addition salts of tricyclic 3,4-propinoperhydropurine, e.g., the hydrochloride salt of tricyclic 3,4-propinoperhydropurine, a basic enhancer such as a hydroxide-releasing agent will neutralize the drug during manufacture of the transdermal system, resulting in a final drug delivery device in which the drug is present in nonionized, neutral form, preferably along with an excess of the basic compound to serve as a permeation enhancer.
In a preferred delivery system, an adhesive overlayer that also serves as a backing for the delivery system is used to better secure the patch to the body surface.
This overlayer is sized such that it extends beyond the drug reservoir so that adhesive on the overlayer comes into contact with the body surface. The overlayer is useful because the adhesive/drug reservoir layer may lose its adhesion a few hours after application due to hydration. By incorporating such an adhesive overlayer, the delivery system remains in place for the required period of time.
Other types and configurations of transdermal drug delivery systems may also be used in conjunction with the method of the present invention, i.e., the use of a hydroxide-releasing agent as a permeation enhancer, as will be appreciated by those skilled in the art of transdermal drug delivery. See, for example, Ghosh, Transdermal and Topical Drug Delivery Systems (Interpharm Press, 1997), particularly Chapters 2 and 8. In addition, two or more transdermal delivery systems may be combined.
In another embodiment of the present invention, a physical transdennal pei7neation enhancement method selected from iontophoresis, phonophoresis, sono-macroporation, thermal modulation, magnetic modulation, and mechanical modulation, may be einployed either alone, or in combination with another physical or cheinical permeation enhancer. Exainples of most of these methods can be found in, for example, "Drug Permeation Enhancement, Theory and Applications,"
D.S.T.
Hsieh, ed., Marcel Deldcer, New Yorlc, New York (1994).
Particularly preferred methods of perineation enhancement are phonoporesis and sono-macroporation. These methods offer several advantages including bypassing the gastrointestinal degradation and hepatic first-pass metabolism encountered in oral administration of medicaments, iinproves patient compliance since it is non-invasive, may eliminate the need to use chemical permeation enhances which can damage the skin, can be used to deliver the active ingredients in ionic or non-ionic form, works well with both aqueous and non-aqueous carriers, can deliver the actives to deep subcutaneous tissues, and these methods can be used in combination with other transdermal delivery systems such as transdermal patches, and/or permeation enhancers. Phonoporesis has been used to deliver local anesthetics in, for example, E.J. Novalc, Arch. Phys. Med. Rehabil., May, 231 (1964), and H.A.E.
Benson, J.C. McEhiay, and R. Harland, Int. J. Pharm., 44, 65 (1988). Suitable conditions for phonoporesis are described in, "Y. Sun and J.C. Liu, "Transdermal Drug Deliverty by Phonoporesis: Basics, Mechanimis, and Tecluliques of Application, Chapter 15, "Drug Permeation Enhancement Theory and Applications, D.S.T. Hsieh, Ed., Marcel Delclcer, New Yorlc, New York (1994), the disclosure of which is hereby incorporated by reference for the purpose of describing suitable phonoporesis conditions.
If phonoporesis is to be employed, the composition should contain a suitable coupling agent for transfer of acoustic energy from the surface of the transducer to a patient. Water is a preferred coupling agent since there is only a small difference between the acoustic impedance of water and that of soft tissue.
Alternatively, commercially available coupling agents, such as aqueous thixotropic gels, glycerol, and mineral oil, may be employed.
hl carrying out phonoporesis, frequencies of from about 0.05 MHz to about 20 MHz may be employed. More preferably, frequencies of from about 3 MHz to about 16 MHz are used. The ultrasound may be continuous or pulsed and the intensity and duration of the treatment can be determined by a person slcilled in the art depending on the patient and the desired level of drug delivery required. Typically, intensities of less than about 2 W/cm2 are applied in phonoporesis.
Alternatively, sono-macroporation may be employed. If sono-macroporation is employed, typically acoustic intensities of more than 2 W/cm2 up to about W/cm2 will be employed in combination with frequencies of about 10-30 kHz.
Sono-macroporation is most useful for enhancing the permeation of larger molecules having molecular weights of about 400-600 kDa.
The phycotoxins employed in the present invention are non-protein, low molecular weight compounds of between 289 and 450 daltons. This provides several advantages over prior art compositions used for similar purposes. First, since the phycotoxins are non-protein, the likelihood of allergic reactions to the phycotoxins is very low. Second, the small size of the phycotoxins makes them excellent candidates for transdermal delivery. Also, the phyxotoxins of the present invention are very potent, relative to Botulin A toxin, and thus smaller amounts can be used to achieve longer lasting effects. In addition, the phycotoxins of the present invention often exhibit a shorter time period until the effect is realized, in comparison to Botulin A
toxin. Also, the small size of the phycotoxins allows them to be passed out of the body relatively quicldy, thereby reducing the risk of harmful side effects or toxin buildup in the body.
The transfer of medicaments through the slcin of a mammal other than man may required an increased concentration of the active ingredient(s) to over come the thicker skin of mammals or the fur covering most mammals have without resorting to shaving the slcin to remove the hair.
In one embodiment of the invention, the compounds of the invention are used in combination with an effective amount of another local anesthetic. In this embodiment, the pharmaceutical compositions of the invention comprise an effective amount of a local anesthetic such as benzocaine, tetracaine, mepivacaine, prilocaine, etidocaine, bupivacaine, lidocaine or similar local anesthetics, ketamine, diazepam, acepromazine, butorphanol, xylazine, midazolam, telazol, eutectic mixtures of local anesthetics (EMLA's), Betacaine-LATM (lidocaine, procaine and dibucaine), TopicaineTM (lidocaine in a gel microemulsion), AmethocaineTM gel (tetracaine), TAC
(tetracaine, adrenaline and cocaine), LET (lidocaine, epinephrine, and tetracaine), and S-caineTM patch (a eutectic mixture of lidocaine and tetracaine, with a disposable oxygen activated heating element), and combinations thereof and an effective amount of at least one tricyclic 3,4-propinoperhydropurine. Also, liposomal delivery systems may be employed in the compositions and methods of the present invention. The combination may be used in any veterinaiy application in which the compounds of the invention.
The dosage of the active agent can vary a great deal, and will depend on a variety of factors, including the disease or condition to be treated, the desired effect, the ability and speed of the active agent to reach its intended target, and other factors within the particular knowledge of the mammal and physician. Preferred single doses will typically contain on the order of about 1 to about 1000 untis of activity, more preferably, more than 32 units up to about 1000 units of activity, even more preferably, about 50 to 500 units of activity, and most preferably, from 75 to 200 units of activity. In other terms, dosages may range from about 0.01-14.3 units/kg bodyweight, and, optionally, 0.1-5.7 units/kg bodyweight. This corresponds to 0.004-3.6 g/lcg bodyweight, and, optionally, 0.04-1.4 g/kg bodyweight.
In one aspect, the present invention relates to a method for the treatment of animal myalgias. In another aspect, the present invention relates to the treatment of muscle spasms in animals. In a further aspect, the present invention relates to a method of facilitating wound healing by treatment of one or more muscles of an animal to effect muscle relaxation in the vicinity of the wound. This aspect of the invention is particularly useful for post-surgical treatment.
In anotller aspect, the preseilt invention relates to the use of compounds of the present invention as a local anesthetic in animals. This aspect of the invention may facilitate various treatments of animals that require anesthetics by the provision of an effective local anesthesia witllout causing significant drowsiness and lethargy in the animal. Examples of each of these aspects of the present invention are given below to demonstrate specific uses thereof. Dosages for each aspect of the invention are as described above.
The practice of the present invention will employ, unless otherwise indicated, conventional techniques of drug formulation, particularly topical drug formulation, which are within the skill of the art. Such techniques are fully explained in the literature. See Remington: The Science and Practice of Pharmacy, cited supra, as well as Goodman & Gilman's The Pharmacological Basis of Therapeutics, 9th Ed. (New York: McGraw-Hill, 1996).
EXAMPLES
Use of GTX in animal myalgias and muscular spasms: equine, canine and others Current treatment for animal myalgias and muscular spasms due to trauma or physical stress, particularly in race horses, is the use of systemic muscle relaxants.
This treatment induces a general state of drowsiness and malaise in the animals, causing them to lay down and in many instances, decrease their food consuinption.
Therefore, there is the need for a local treatment of the muscle spasm which is causing the myalgia.
For the purpose of treating myalgias and muscle spasms, a local infiltration of 0.04-1.4 ug/lcg bodyweight of a mixture of GTX 2 and GTX 3 in the affected muscle will generally result in pain relief. Specifically, in a horse, the composition may be injected in the neck muscles (brachio cephalic, sterno cephalic or infraspinosum muscles). Particularly cominon are the myalgias of the lumbar region of the horse, where the composition can be injected in the great dorsal, supraspinosum or lumbodorsal fascia muscles. For administration, a total dose of 0.004-3.6 ug/kg bodyweight of one or more GTX compounds is injected at different points of the animal muscle (200 to 500 ul of a solution of GTX per injection point). The dose may be repeated, as needed, daily, after two days, or after three days, and again after that depending on the status of the condition.
Use of GTX post-surgery for repair of a third degree rectovaginal laceration or a rectovaginal fistula in the mare/cow A third degree perineal laceration corresponds to a complete disruption of tissue between the rectum and vestibule, creating a common rectal and vestibular vault. This condition is referred to as a rectovaginal or rectovestigular laceration.
These lacerations usually allow fecal contamination of the cow/mare's vagina witll subsequent bacterial infection of the vagina, cervix and uterus. In the rectovestibular fistulas, the tissue between the rectum and vestibule is coinpletely perforated but the perineal body, or caudal portion of it, remains intact. Surgical correction, and reestablishinent of the normal anatomic structures are iinperative. However, attempts to repair the laceration immediately after injury are usually unsuccessful because the lacerated tissue rapidly becomes inflamed and edematous. Furthermore, contraction of the muscles of the rectum and vagina widen and lengthen the wound. Post surgery, wound breakdown occurs as a result of rectum inuscle contraction during defecation with a relapse of the condition. Therefore it is critical that the feces are soft before the repair is attempted, otherwise fecal impaction at the surgical site or/and wound breakdown will occur.
In this context, use of GTX post surgery, in the local muscles at the terminus of the rectum and anal sphincter, will release some of the contraction pressure over the wound sutures allowing for a smoother healing of the wound. For this purpose, 0.004-3.6 ug/kg bodyweight of a mixture of GTX 2 and GTX 3 are infiltrated post-surgery, while the mare/cow is still under anesthesia, in the muscles in the perineal area (200 ul to 500 ul of solution per site), including the anal sphincter.
This procedure is repeated under mild sedation for tllree days post surgery to ensure healing of the wound. Further applications of the product are performed on an as required basis, daily, after two days, or after three days, and again after that depending on the status of the condition.
Use of GTX during an esophageal obstruction in the horse Horses frequently experience obstruction of the esophageous due to a foreign object (e.g. an apple) stuck somewhere in the first two thirds of the esophageous.
Currently, the animal has to be anesthesized in order to have the blocking body removed, with the consequence that the horse must lay down during the procedure, making it more cumbersome to carry out. In this context, a combined treatment with a local muscle relaxant injected in the muscles of the esophagous, plus some systemic tranquilizers, would be a benefit for the elimination of the obstruction without the need for general anesthesia.
Administration of one or more GTX compounds in the muscles of the esophagous will result in muscle relaxation, which will allow removal of the foreign object in a standing position. 0.004-3.6 ug/kg bodyweight of the GTX compounds can be administered for this purpose.
Other aspects, advantages and modifications will be apparent to those skilled in the art to which the invention pertains. All patents, patent applications, j ournal articles and other references cited herein are incorporated by reference in their entireties.
The pharmaceutical preparations of the invention are administered either transdermally or by injection, locally in the muscle or in the vicinity of the muscle that is to be paralyzed or prevented from contracting. The application should be in amounts sufficient to provide from 1-1000 units (U) of activity to the muscle, per dose. The effect is immediately apparent, generally occurring within a maximum of 30 seconds to five minutes after administration of the active compound to the treatment area. The maximum effect is generally achieved within 15 minutes of administration of the active compound to the treatment area. Its effective duration depends on the dose administered, the muscle in question, as well as the volume and specific composition administered. This is the pattern for substantially all veterinary applications and pathologies.
More preferably, each dose includes more than 32 units of activity up to a maxiinum of about 1000 units of activity. Even more preferably, each dose includes from about 50 to about 500 units of activity. Most preferably, each dose includes about 75 to about 200 units of activity. Doses may be repeated from time-to-time, as needed, to continue muscle relaxation until the desired effect is obtained.
According to one method of the present invention, mammals are treated by direct, local injection of a coinposition of the invention into a inuscle or in the vicinity of a muscle. Preferably, the muscle at the location of injection exhibits elevated tone or spasms, tliough this is not necessary for the effectiveness of all treatments. In a preferred embodiment, each injection should be limited to not more than two milliliters of composition, including solvents, adjuvants and/or carrier materials.
Administration may be accomplished, for example, using a one milliliter, tuberculin-type disposable syringe with a twenty-seven to thirty gauge needle.
Alternatively, for certain methods, it may be desirable to administer the dosage using an endoscope such as that described in U.S. Patent No. 5,674,205, the disclosure of which is hereby incoiporated by reference for the purpose of providing details of an endoscope suitable for use in the inethod of the present invention.
Alternatively, the pharmaceutical compositions of the invention may be applied locally to the skin for transdennal delivery. To form such a preparation, an effective amount of the pharnnaceutical compositions of the invention is added to a pharmacologically acceptable carrier. The composition, when applied to the skin, may be in any form suitable for application to the body surface, and may coinprise, for exainple, a cream, lotion, solution, gel, ointment, paste or the like, and/or may be prepared so as to contain liposomes, micelles, and/or microspheres. The composition may be directly applied to the body surface or may involve use of a drug delivery device. Thus, a fornnulation or drug reservoir may be aqueous, i.e., contain water, or may be nonaqueous and used in combination with an occlusive overlayer so that moisture evaporating from the body surface is maintained within the formulation or transdermal system during drug achninistration. In some cases, however, e.g., with an occlusive gel, a non-aqueous formulation may be used with or without an occlusive layer.
The delivery of drugs transdermally provides many advantages; primarily, such a means of delivery is a comfortable, convenient and noninvasive way of administering drugs. The variable rates of absorption and metabolism encountered in oral treatment are avoided, and other inherent inconveiuences--e.g., gastrointestinal irritation and the like--are eliminated as well. Transdermal drug delivery also makes possible a high degree of control over blood concentrations of any particular drug.
Slcin is a structurally complex, relatively thick membrane. Molecules moving from the enviromnent into and through intact slcin must first penetrate the stratum corneum and any material on its surface. They must then penetrate the viable epidermis, the papillary dermis, and the capillary walls into the blood stream or lymph channels. To be so absorbed, molecules must overcome a different resistance to penetration in each type of tissue. Transport across the skin membrane is thus a complex pllenomenon. However, it is the cells of the stratum corneum (the outer layer of the epidermis), which present the primary barrier to absorption of topical compositions or transdermally administered drugs. The stratum corneum is a thin layer of dense, highly keratinized cells approximately 10-15 microns thick over most of the body. It is believed to be the high degree of keratinization within these cells as well as their dense packing which creates in most cases a substantially impermeable barrier to drug penetration. With many drugs, the rate of permeation through the skin is extremely low without the use of some means to enhance the permeability of the skin.
In order to increase the rate at which a drug penetrates through the skin, then, various approaches have been followed, each of which involves the use of either a chemical penetration enhancer or a physical penetration enhancer. Physical enhancement of skin permeation includes, for example, electrophoretic techniques such as iontophoresis. Chemical enhancers are compounds that are administered along with the drug (or in some cases the skin may be pretreated with a chemical enhancer) in order to increase the permeability of the stratum comeum, and thereby provide for enhanced penetration of the drug through the skin. Ideally, such chemical penetration enhancers (or "permeation enhancers," as the compounds are referred to herein) are compounds that are innocuous and serve merely to facilitate diffusion of the drug through the stratum corneum.
In another aspect, the invention pertains to a method, composition and drug delivery system for increasing the rate at which the active agent, permeates through the body surface of a patient. The method involves administering the agent to a predetermined area of the patient's body surface in combination with a chemical permeation enhancer, such as a hydroxide-releasing agent in an amount effective to enhance the flux of the agent through the body surface without causing damage thereto, or in combination with an ultrasound treatment. Other suitable chemical permeation enhancers are described in, for example, W.R. Pfister and D.S. T.
Hsieh, - - - -"Permeation Enhancers Compatible with Transdermal Drug Delivery Systems, Part I:
Selection and Formulation Considerations," Pharnz. Technol., September 1990, and W.R. Pfister and D.S.T. Hsieh, "Permeation Enhancers Coinpatible with Transdermal Drug Delivery Systems, Part 11: System Design Considerations," Phaf=rn.
Technol., October 1990, the disclosures of which are hereby incorporated by reference to describe suitable chemical permeation enliancers.
Thus, the present method of transdermally delivering the active agent may vary, but necessarily involves application of a composition containing a tricyclic 3,4-propinoperhydropurine to a predetermined area of the skin or mucosal tissue for a period of time sufficient to provide an effective blood level or penetration level of drug. The method may involve direct application of the composition as an ointment, gel, cream, or the like, or may involve use of a drug delivery device as taught in the art, e.g., in U.S. Patent Nos. 4,915,950, 4,906,463, 5,091,186 or 5,246,705, the disclosures of which are hereby incorporated by reference for the purpose of describing specific transdermal drug delivery devices, or as described below.
Various compounds for enhancing the permeability of slcin are known in the art and can be used in the compositions of the present invention. Compounds that may be used to enhance slcin permeability include: the sulfoxides dimethylsulfoxide (DMSO) and decylmethylsulfoxide (Clo MSO); ethers such as diethylene glycol monoethyl ether (available commercially as TranscutolTM) and diethylene glycol monomethyl ether; surfactants such as sodium laurate, sodium lauryl sulfate, cetyltrimethylanunonium bromide, benzalkonium chloride, Poloxamer (231, 182, 184), Tween (20, 40, 60, 80) and lecithin (U.S. Pat. No. 4,783,450); the 1-substituted azacycloheptan-2-ones, particularly 1-n-dodecylcyclazacycloheptan-2-one (available under the trademarlc AzoneTM from Nelson Research & Development Co., Irvine, Calif.; see U.S. Pat. Nos. 3,989,816, 4,316,893, 4,405,616 and 4,557,934);
alcohols such as ethanol, propanol, octanol, benzyl alcohol, and the like; fatty acids such as lauric acid, oleic acid and valeric acid; fatty acid esters such as isopropyl myristate, isopropyl palmitate, methylpropionate, and ethyl oleate; polyols and esters thereof such as propylene glycol, ethylene glycol, glycerol, butanediol, polyethylene glycol, and polyethylene glycol monolaurate (PEGML; see, e.g., U.S. Pat. No.
4,568,343);
amides and other nitrogenous conlpounds such as urea, dimetlzylacetamide (DMA), diinethylformamide (DMF), 2-pyrrolidone, 1-methyl-2-pyrrolidone, ethanol amine, diethanol amine and triethanolamine; terpenes; alkanones, and organic acids, particularly salicylic acid and salicylates, citric acid and succinic acid.
Percutaneous Penetration Enhancers, eds. Smith et al. (CRC Press, 1995) provides an excellent overview of the field and further background information on a number of chemical and physical enhancers.
Transdermal Delivery Systems An alternative and preferred method for administering a tricyclic 3,4-propinoperhydropurine transdermally involves the use of a drug delivery system, e.g., a topical or transdermal "patch," wherein the active agent is contained within a laminated structure that is to be affixed to the slcin. In such a structure, the active agent is contained in a layer, or "reservoir," underlying an upper backing layer. The laininated structure may contain a single reservoir, or it may contain multiple reservoirs.
In one embodiment, the reservoir comprises a polymeric matrix of a pharmaceutically acceptable adhesive material that serves to affix the system to the skin during drug delivery; typically, the adhesive material is a pressure-sensitive adhesive (PSA) that is suitable for long-term slcin contact, and which should be physically and chemically coinpatible with the active agent, hydroxide-releasing agent, and any carriers, vehicles or other additives that are present.
Examples of suitable adhesive materials include, but are not limited to, the following:
polyethylenes; polysiloxanes; polyisobutylenes; polyacrylates;
polyacrylamides;
polyurethanes; plasticized ethylene-vinyl acetate copolymers; and tacky rubbers such as polyisobutene, polybutadiene, polystyrene-isoprene copolymers, polystyrene-butadiene copolymers, and neoprene (polychloroprene). Preferred adhesives are polyisobutylenes.
The backing layer functions as the primary structural element of the transdermal system and provides the device with flexibility an, preferably, occlusivity. The material used for the baclcing layer should be inert and incapable of absorbing drug, hydroxide-releasing agent or components of the formulation contained within the device. The backing is preferably comprised of a flexible elastoineric material that serves as a protective covering to prevent loss of drug and/or vehicle via transmission tlirough the upper surface of the patch, and will preferably impart a degree of occlusivity to the system, such that the area of the body surface covered by the patch becomes hydrated during use. The material used for the backing layer should permit the device to follow the contours of the slcin and be worn comfortably on areas of slcin such as at joints or other points of flexure, that are normally subjected to mechanical strain with little or no likelihood of the device disengaging from the skin due to differences in the flexibility or resiliency of the skin and the device. The materials used as the backing layer are either occlusive or peimeable, as noted above, although occlusive baclcings are preferred, and are generally derived from synthetic polymers (e.g., polyester, polyethylene, polypropylene, polyurethane, polyvinylidine chloride, and polyether amide), natural polymers (e.g., cellulosic materials), or macroporous woven and nonwoven materials.
During storage and prior to use, the laminated structure includes a release liner. Immediately prior to use, this layer is removed from the device so that the system may be affixed to the slcin. The release liner should be made from a drug/vehicle impermeable material, and is a disposable element which serves only to protect the device prior to application. Typically, the release liner is formed from a material impermeable to the pharmacologically active agent and the hydroxide-releasing agent, and which is easily stripped from the transdermal patch prior to use.
In an alternative embodiment, the drug-containing reservoir and slcin contact adhesive are present as separate and distinct layers, with the adhesive underlying the reservoir. In such a case, the reservoir may be a polymeric matrix as described above.
Alternatively, the reservoir may be comprised of a liquid or semisolid formulation contained in a closed compartment or "pouch," or is may be a hydrogel reservoir, or may take some other form. Hydrogel reservoirs are particularly preferred herein. As will be appreciated by those skilled in the art, hydrogels are macromolecular networlcs that absorb water and thus swell but do not dissolve in water. That is, hydrogels contain hydrophilic functional groups that provide for water absorption, but the hydrogels are comprised of crosslinked polymers that give rise to aqueous insolubility. Generally, then, hydrogels are comprised of crosslinked hydrophilic polymers such as a polyurethane, a polyvinyl alcohol, a polyacrylic acid, a polyoxyethylene, a polyvinylpyrrolidone, a poly(hydroxyethyl methacrylate) (poly(HEMA)), or a copolymer or mixture thereof Particularly preferred hydrophilic polymers are copolymers of HEMA and polyvinylpyrrolidone.
Additional layers, e.g., intermediate fabric layers and/or rate-controlling membranes, may also be present in any of these drug delivery systems. Fabric layers may be used to facilitate fabrication of the device, while a rate-controlling membrane may be used to control the rate at which a component permeates out of the device.
The component may be a drug, a hydroxide-releasing agent, an additional enhancer, or some other component contained in the drug delivery system.
A rate-controlling membrane, if present, will be included in the system on the skin side of one or more of the drug reservoirs. The materials used to form such a membrane are selected to limit the flux of one or more components contained in the drug formulation. Representative materials useful for forming rate-controlling membranes include polyolefins such as polyethylene and polypropylene, polyamides, polyesters, ethylene-ethacrylate copolymer, ethylene-vinyl acetate copolymer, ethylene-vinyl methylacetate copolymer, ethylene-vinyl ethylacetate copolymer, ethylene-vinyl propylacetate copolymer, polyisoprene, polyacrylonitrile, ethylene-propylene copolymer, and the like.
Generally, the underlying surface of the transdermal device, i.e., the skin contact area, has an area in the range of about 5 cm2 to 200 cm2, preferably 5 cm2 to 100 cm2, more preferably 20 cm2 to 60 cm2. That area will vary, of course, with the amount of the drug to be delivered and the flux of the drug through the body surface.
Larger patches will be necessary to accommodate larger quantities of drug, while smaller patches can be used for small quantities of drug and/or drugs that exhibit a relatively high permeation rate.
Such drug delivery systems may be fabricated using conventional coating and laminating techniques known in the art. For example adhesive matrix systems can be prepared by casting a fluid admixture adhesive, drug and vehicle onto the backing layer followed by lamination of the release liner. Similarly the adhesive mixture may be cast onto the release liner, followed by lamination of the release liner.
Alternatively, the drug reservoir may be prepared in the absence of drug or excipient, and then loaded by "soaking" in a drug/vehicle mixture. In general, transdermal systems of the invention are fabricated by solvent evaporation, film casting, melt extrusion, thin film lamination, die cutting, or the like. The hydroxide-releasing agent will generally be incorporated into the device during patch manufacture rather than subsequent to preparation of the device. For active agents that are obtained in salt form, an enhancer that doubles as a neutralizing agent is incorporated into the device during patch manufacture rather than subsequent to preparation of the device.
Thus, for acid addition salts of tricyclic 3,4-propinoperhydropurine, e.g., the hydrochloride salt of tricyclic 3,4-propinoperhydropurine, a basic enhancer such as a hydroxide-releasing agent will neutralize the drug during manufacture of the transdermal system, resulting in a final drug delivery device in which the drug is present in nonionized, neutral form, preferably along with an excess of the basic compound to serve as a permeation enhancer.
In a preferred delivery system, an adhesive overlayer that also serves as a backing for the delivery system is used to better secure the patch to the body surface.
This overlayer is sized such that it extends beyond the drug reservoir so that adhesive on the overlayer comes into contact with the body surface. The overlayer is useful because the adhesive/drug reservoir layer may lose its adhesion a few hours after application due to hydration. By incorporating such an adhesive overlayer, the delivery system remains in place for the required period of time.
Other types and configurations of transdermal drug delivery systems may also be used in conjunction with the method of the present invention, i.e., the use of a hydroxide-releasing agent as a permeation enhancer, as will be appreciated by those skilled in the art of transdermal drug delivery. See, for example, Ghosh, Transdermal and Topical Drug Delivery Systems (Interpharm Press, 1997), particularly Chapters 2 and 8. In addition, two or more transdermal delivery systems may be combined.
In another embodiment of the present invention, a physical transdennal pei7neation enhancement method selected from iontophoresis, phonophoresis, sono-macroporation, thermal modulation, magnetic modulation, and mechanical modulation, may be einployed either alone, or in combination with another physical or cheinical permeation enhancer. Exainples of most of these methods can be found in, for example, "Drug Permeation Enhancement, Theory and Applications,"
D.S.T.
Hsieh, ed., Marcel Deldcer, New Yorlc, New York (1994).
Particularly preferred methods of perineation enhancement are phonoporesis and sono-macroporation. These methods offer several advantages including bypassing the gastrointestinal degradation and hepatic first-pass metabolism encountered in oral administration of medicaments, iinproves patient compliance since it is non-invasive, may eliminate the need to use chemical permeation enhances which can damage the skin, can be used to deliver the active ingredients in ionic or non-ionic form, works well with both aqueous and non-aqueous carriers, can deliver the actives to deep subcutaneous tissues, and these methods can be used in combination with other transdermal delivery systems such as transdermal patches, and/or permeation enhancers. Phonoporesis has been used to deliver local anesthetics in, for example, E.J. Novalc, Arch. Phys. Med. Rehabil., May, 231 (1964), and H.A.E.
Benson, J.C. McEhiay, and R. Harland, Int. J. Pharm., 44, 65 (1988). Suitable conditions for phonoporesis are described in, "Y. Sun and J.C. Liu, "Transdermal Drug Deliverty by Phonoporesis: Basics, Mechanimis, and Tecluliques of Application, Chapter 15, "Drug Permeation Enhancement Theory and Applications, D.S.T. Hsieh, Ed., Marcel Delclcer, New Yorlc, New York (1994), the disclosure of which is hereby incorporated by reference for the purpose of describing suitable phonoporesis conditions.
If phonoporesis is to be employed, the composition should contain a suitable coupling agent for transfer of acoustic energy from the surface of the transducer to a patient. Water is a preferred coupling agent since there is only a small difference between the acoustic impedance of water and that of soft tissue.
Alternatively, commercially available coupling agents, such as aqueous thixotropic gels, glycerol, and mineral oil, may be employed.
hl carrying out phonoporesis, frequencies of from about 0.05 MHz to about 20 MHz may be employed. More preferably, frequencies of from about 3 MHz to about 16 MHz are used. The ultrasound may be continuous or pulsed and the intensity and duration of the treatment can be determined by a person slcilled in the art depending on the patient and the desired level of drug delivery required. Typically, intensities of less than about 2 W/cm2 are applied in phonoporesis.
Alternatively, sono-macroporation may be employed. If sono-macroporation is employed, typically acoustic intensities of more than 2 W/cm2 up to about W/cm2 will be employed in combination with frequencies of about 10-30 kHz.
Sono-macroporation is most useful for enhancing the permeation of larger molecules having molecular weights of about 400-600 kDa.
The phycotoxins employed in the present invention are non-protein, low molecular weight compounds of between 289 and 450 daltons. This provides several advantages over prior art compositions used for similar purposes. First, since the phycotoxins are non-protein, the likelihood of allergic reactions to the phycotoxins is very low. Second, the small size of the phycotoxins makes them excellent candidates for transdermal delivery. Also, the phyxotoxins of the present invention are very potent, relative to Botulin A toxin, and thus smaller amounts can be used to achieve longer lasting effects. In addition, the phycotoxins of the present invention often exhibit a shorter time period until the effect is realized, in comparison to Botulin A
toxin. Also, the small size of the phycotoxins allows them to be passed out of the body relatively quicldy, thereby reducing the risk of harmful side effects or toxin buildup in the body.
The transfer of medicaments through the slcin of a mammal other than man may required an increased concentration of the active ingredient(s) to over come the thicker skin of mammals or the fur covering most mammals have without resorting to shaving the slcin to remove the hair.
In one embodiment of the invention, the compounds of the invention are used in combination with an effective amount of another local anesthetic. In this embodiment, the pharmaceutical compositions of the invention comprise an effective amount of a local anesthetic such as benzocaine, tetracaine, mepivacaine, prilocaine, etidocaine, bupivacaine, lidocaine or similar local anesthetics, ketamine, diazepam, acepromazine, butorphanol, xylazine, midazolam, telazol, eutectic mixtures of local anesthetics (EMLA's), Betacaine-LATM (lidocaine, procaine and dibucaine), TopicaineTM (lidocaine in a gel microemulsion), AmethocaineTM gel (tetracaine), TAC
(tetracaine, adrenaline and cocaine), LET (lidocaine, epinephrine, and tetracaine), and S-caineTM patch (a eutectic mixture of lidocaine and tetracaine, with a disposable oxygen activated heating element), and combinations thereof and an effective amount of at least one tricyclic 3,4-propinoperhydropurine. Also, liposomal delivery systems may be employed in the compositions and methods of the present invention. The combination may be used in any veterinaiy application in which the compounds of the invention.
The dosage of the active agent can vary a great deal, and will depend on a variety of factors, including the disease or condition to be treated, the desired effect, the ability and speed of the active agent to reach its intended target, and other factors within the particular knowledge of the mammal and physician. Preferred single doses will typically contain on the order of about 1 to about 1000 untis of activity, more preferably, more than 32 units up to about 1000 units of activity, even more preferably, about 50 to 500 units of activity, and most preferably, from 75 to 200 units of activity. In other terms, dosages may range from about 0.01-14.3 units/kg bodyweight, and, optionally, 0.1-5.7 units/kg bodyweight. This corresponds to 0.004-3.6 g/lcg bodyweight, and, optionally, 0.04-1.4 g/kg bodyweight.
In one aspect, the present invention relates to a method for the treatment of animal myalgias. In another aspect, the present invention relates to the treatment of muscle spasms in animals. In a further aspect, the present invention relates to a method of facilitating wound healing by treatment of one or more muscles of an animal to effect muscle relaxation in the vicinity of the wound. This aspect of the invention is particularly useful for post-surgical treatment.
In anotller aspect, the preseilt invention relates to the use of compounds of the present invention as a local anesthetic in animals. This aspect of the invention may facilitate various treatments of animals that require anesthetics by the provision of an effective local anesthesia witllout causing significant drowsiness and lethargy in the animal. Examples of each of these aspects of the present invention are given below to demonstrate specific uses thereof. Dosages for each aspect of the invention are as described above.
The practice of the present invention will employ, unless otherwise indicated, conventional techniques of drug formulation, particularly topical drug formulation, which are within the skill of the art. Such techniques are fully explained in the literature. See Remington: The Science and Practice of Pharmacy, cited supra, as well as Goodman & Gilman's The Pharmacological Basis of Therapeutics, 9th Ed. (New York: McGraw-Hill, 1996).
EXAMPLES
Use of GTX in animal myalgias and muscular spasms: equine, canine and others Current treatment for animal myalgias and muscular spasms due to trauma or physical stress, particularly in race horses, is the use of systemic muscle relaxants.
This treatment induces a general state of drowsiness and malaise in the animals, causing them to lay down and in many instances, decrease their food consuinption.
Therefore, there is the need for a local treatment of the muscle spasm which is causing the myalgia.
For the purpose of treating myalgias and muscle spasms, a local infiltration of 0.04-1.4 ug/lcg bodyweight of a mixture of GTX 2 and GTX 3 in the affected muscle will generally result in pain relief. Specifically, in a horse, the composition may be injected in the neck muscles (brachio cephalic, sterno cephalic or infraspinosum muscles). Particularly cominon are the myalgias of the lumbar region of the horse, where the composition can be injected in the great dorsal, supraspinosum or lumbodorsal fascia muscles. For administration, a total dose of 0.004-3.6 ug/kg bodyweight of one or more GTX compounds is injected at different points of the animal muscle (200 to 500 ul of a solution of GTX per injection point). The dose may be repeated, as needed, daily, after two days, or after three days, and again after that depending on the status of the condition.
Use of GTX post-surgery for repair of a third degree rectovaginal laceration or a rectovaginal fistula in the mare/cow A third degree perineal laceration corresponds to a complete disruption of tissue between the rectum and vestibule, creating a common rectal and vestibular vault. This condition is referred to as a rectovaginal or rectovestigular laceration.
These lacerations usually allow fecal contamination of the cow/mare's vagina witll subsequent bacterial infection of the vagina, cervix and uterus. In the rectovestibular fistulas, the tissue between the rectum and vestibule is coinpletely perforated but the perineal body, or caudal portion of it, remains intact. Surgical correction, and reestablishinent of the normal anatomic structures are iinperative. However, attempts to repair the laceration immediately after injury are usually unsuccessful because the lacerated tissue rapidly becomes inflamed and edematous. Furthermore, contraction of the muscles of the rectum and vagina widen and lengthen the wound. Post surgery, wound breakdown occurs as a result of rectum inuscle contraction during defecation with a relapse of the condition. Therefore it is critical that the feces are soft before the repair is attempted, otherwise fecal impaction at the surgical site or/and wound breakdown will occur.
In this context, use of GTX post surgery, in the local muscles at the terminus of the rectum and anal sphincter, will release some of the contraction pressure over the wound sutures allowing for a smoother healing of the wound. For this purpose, 0.004-3.6 ug/kg bodyweight of a mixture of GTX 2 and GTX 3 are infiltrated post-surgery, while the mare/cow is still under anesthesia, in the muscles in the perineal area (200 ul to 500 ul of solution per site), including the anal sphincter.
This procedure is repeated under mild sedation for tllree days post surgery to ensure healing of the wound. Further applications of the product are performed on an as required basis, daily, after two days, or after three days, and again after that depending on the status of the condition.
Use of GTX during an esophageal obstruction in the horse Horses frequently experience obstruction of the esophageous due to a foreign object (e.g. an apple) stuck somewhere in the first two thirds of the esophageous.
Currently, the animal has to be anesthesized in order to have the blocking body removed, with the consequence that the horse must lay down during the procedure, making it more cumbersome to carry out. In this context, a combined treatment with a local muscle relaxant injected in the muscles of the esophagous, plus some systemic tranquilizers, would be a benefit for the elimination of the obstruction without the need for general anesthesia.
Administration of one or more GTX compounds in the muscles of the esophagous will result in muscle relaxation, which will allow removal of the foreign object in a standing position. 0.004-3.6 ug/kg bodyweight of the GTX compounds can be administered for this purpose.
Other aspects, advantages and modifications will be apparent to those skilled in the art to which the invention pertains. All patents, patent applications, j ournal articles and other references cited herein are incorporated by reference in their entireties.
Claims (22)
1. A method of facilitating the healing of a wound in an animal comprising the step of administering to an animal an effective amount of a composition comprising at least one tricyclic 3,4-propinoperhydropurine represented by formula (I) set forth below:
wherein R1 and R5 are independently selected from the group consisting of -H
and -OH; R2 and R3 are independently selected from the group consisting of -H and -SO3;
and R4 is selected from the group consisting of -H, -OH, -COONH2, -COONHSO-3 and -COOCH3, with the proviso that either one of R2 and R3 must be -OSO-3, or must be -COONHSO-3, and a pharmacologically acceptable carrier.
wherein R1 and R5 are independently selected from the group consisting of -H
and -OH; R2 and R3 are independently selected from the group consisting of -H and -SO3;
and R4 is selected from the group consisting of -H, -OH, -COONH2, -COONHSO-3 and -COOCH3, with the proviso that either one of R2 and R3 must be -OSO-3, or must be -COONHSO-3, and a pharmacologically acceptable carrier.
2. The method of claim 1, wherein the composition is injected into a muscle or proximate to a muscle.
3. The method of claim 1, where in the method is applied to an animal to facilitate post surgical healing.
4. The method of claim 1, wherein the at least one compound of the formula (I) is selected from the group consisting of: GTX-1, GTX-2, GTX-3, GTX-4 and GTX-
5.
5. The method of claim 1, wherein the composition comprises both GTX-2 and GTX-3.
5. The method of claim 1, wherein the composition comprises both GTX-2 and GTX-3.
6. The method of claim 1, wherein the effective amount of said composition contains from about 1 to about 1000 units of activity.
7. The method of claim 1, wherein the effective amount of said composition contains from more than 32 to about 1000 units of activity.
8. The method of claim 1, wherein the effective amount of said composition contains from about 50 to about 1000 units of activity.
9. The method of claim 1, wherein the effective amount of said composition contains from about 50 to about 500 units of activity.
10. The method of claim 1, wherein the effective amount of said composition contains from about 75 to about 200 units of activity.
11. The method of claim 1, wherein the composition is applied topically.
12. The method of claim 11, wherein the topical composition comprises from about 0.0001 % to about 0.01 % by weight of one or more compounds of the formula I, based on the total weight of the composition.
13. A method of effecting the relaxation of a muscle in an animal comprising the step of administering to an animal in a muscle or proximate to a muscle, an effective amount of a composition comprising at least one tricyclic 3,4-propinoperhydropurine represented by formula (I) set forth below:
wherein R1 and R5 are independently selected from the group consisting of -H
and -OH; R2 and R3 are independently selected from the group consisting of -H and -SO3;
and R4 is selected from the group consisting of -H, -OH, -COONH2, -COONHSO-3 and -COOCH3, with the proviso that either one of R2 and R3 must be -OSO-3, or must be -COONHSO-3, and a pharmacologically acceptable carrier.
wherein R1 and R5 are independently selected from the group consisting of -H
and -OH; R2 and R3 are independently selected from the group consisting of -H and -SO3;
and R4 is selected from the group consisting of -H, -OH, -COONH2, -COONHSO-3 and -COOCH3, with the proviso that either one of R2 and R3 must be -OSO-3, or must be -COONHSO-3, and a pharmacologically acceptable carrier.
14. The method of claim 13, wherein the method is applied to an animal to facilitate a treatment that requires anesthetization.
15. The method of claim 13, wherein the method is applied to an animal to treat myalgia or muscle spasms.
16. The method of claim 13, wherein the at least one compound of the formula (I) is selected from the group consisting of: GTX-1, GTX-2, GTX-3, GTX-4 and GTX-5.
17. The method of claim 13, wherein the composition comprises both GTX-2 and GTX-3.
18. The method of claim 13, wherein the effective amount of said composition contains from about 1 to about 1000 units of activity.
19. The method of claim 13, wherein the effective amount of said composition contains from more than 32 to about 1000 units of activity.
20. The method of claim 13, wherein the effective amount of said composition contains from about 50 to about 1000 units of activity.
21. The method of claim 13, wherein the effective amount of said composition contains from about 50 to about 500 units of activity.
22. The method of claim 13, wherein the effective amount of said composition contains from about 75 to about 200 units of activity.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US67793305P | 2005-05-05 | 2005-05-05 | |
| US60/677,933 | 2005-05-05 | ||
| PCT/US2006/017449 WO2006119499A2 (en) | 2005-05-05 | 2006-05-05 | Use of phycotoxins in veterinary applications |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2606315A1 true CA2606315A1 (en) | 2006-11-09 |
Family
ID=37308745
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002606315A Abandoned CA2606315A1 (en) | 2005-05-05 | 2006-05-05 | Use of phycotoxins in veterinary applications |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1877058A4 (en) |
| JP (1) | JP2008540452A (en) |
| AU (1) | AU2006243644A1 (en) |
| CA (1) | CA2606315A1 (en) |
| WO (1) | WO2006119499A2 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3058214A1 (en) * | 2017-03-29 | 2018-10-04 | Siteone Therapeutics, Inc. | 11,13-modified saxitoxins for the treatment of pain |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA01004254A (en) * | 1998-10-27 | 2002-04-24 | Mayo Foundation | Methods for enhancing wound healing. |
| BR0214126A (en) * | 2001-11-15 | 2004-10-13 | Micro Algae Corp | Pharmaceutical composition for interfering with neuronal transmission, preparation for facial rejuvenation, and methods for interfering with neuronal transmission, and muscle contraction |
| EP1824488B1 (en) * | 2004-05-07 | 2017-08-09 | Algenis SpA | Phycotoxins and uses thereof |
-
2006
- 2006-05-05 CA CA002606315A patent/CA2606315A1/en not_active Abandoned
- 2006-05-05 EP EP06752321A patent/EP1877058A4/en not_active Withdrawn
- 2006-05-05 WO PCT/US2006/017449 patent/WO2006119499A2/en active Application Filing
- 2006-05-05 JP JP2008510273A patent/JP2008540452A/en active Pending
- 2006-05-05 AU AU2006243644A patent/AU2006243644A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2008540452A (en) | 2008-11-20 |
| EP1877058A4 (en) | 2008-06-25 |
| AU2006243644A1 (en) | 2006-11-09 |
| EP1877058A2 (en) | 2008-01-16 |
| WO2006119499A2 (en) | 2006-11-09 |
| WO2006119499A3 (en) | 2006-12-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2005244096B2 (en) | Transdermal administration of phycotoxins | |
| KR100764156B1 (en) | Intradermal-penetration agents for topical local anesthetic administration | |
| AU2005244105B2 (en) | Phycotoxins and uses thereof | |
| JP2953625B2 (en) | Method for reducing skin irritation associated with drug / penetration enhancing compositions | |
| AU2001245449A1 (en) | Intradermal-penetration agents for topical local anesthetic administration | |
| ES2228125T3 (en) | SUPPLY SYSTEMS OF PHARMACES ORIGINATED IN LAS MUCOSAS. | |
| JPS60152413A (en) | Composition for local application with improved percutaneousdrug release by menthol | |
| JPH09110680A (en) | Dermatitis-curing strap | |
| CN101496833B (en) | Liquid external preparation for preparing total alkaloids in nux vomica | |
| CA2606315A1 (en) | Use of phycotoxins in veterinary applications | |
| CN111067919A (en) | Spray analgesic | |
| EP1406604A2 (en) | Topical application of muscarinic analgesic drugs such as neostigmine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Dead |